FDA Clears Cepheid's GBS Test as IVD, Lifting Shares 8 Percent

Jul 26, 2006

NEW YORK (GenomeWeb News) – The US Food and Drug Administration has cleared for marketing Cepheid's Xpert clinical molecular diagnostic for Group B Streptococcus, the company said today.

The test runs on the GeneXpert Dx system and is an in vitro diagnostic designed to detect Group B Strep DNA in vaginal and rectal swabs. It is the first test “in a planned menu of Xpert tests” based on the GeneXpert platform, said Cepheid CEO John Bishop.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Breaking News

The Scan

WHO Panel Announced

The World Health Organization has announced the members of its gene-editing committee, according to NPR.

Research Reproducibility Scores

DARPA is working on developing algorithms that gauge the credibility of research findings, Wired reports.

Tests for All Diagnosed

The American Society of Breast Surgeons recommends all women diagnosed with breast cancer be offered genetic testing, the Washington Post says.

This Week in Science

In Science this week: comparison of modern, historical rabbit exomes uncovers parallel evolution after myxoma virus exposure; and more.

Featured White Papers

Controlling Ribonuclease (RNase) with High Irradiance UV LED Light Engines

Optimized NGS Library Preparation with Acoustic Liquid Handling

Main menu